Introduction
Calcinosis cutis is the deposition of calcium in the skin and subcutaneous tissues [1•] (Fig. 1) . It is associated with autoimmune connective tissue diseases (ACTD) including systemic sclerosis (SSc), dermatomyositis (DM), mixed connective tissue diseases (MCTD), and more rarely, systemic lupus erythematosus (SLE) [2•].
Calcinosis in SSc presents as subcutaneous nodules of variable size and shape, typically at sites of recurrent microtrauma. One quarter of patients with SSc have calcinosis at some time during their illness [3], on average more than 7.5 years after the onset of SSc. [2•] The most frequent body sites involved in SSc are the hands (particularly the palmar side of the distal phalanges) and feet. Other common areas that can be affected include the elbows and knees, arms and legs, trunk, and face, in order of frequency [2•, 4••, 5•]. Small single-center studies have related SSc-calcinosis with several clinical features including male gender [6] , digital ulcers [6, 7] , digital tip pitting scars [7] , acro-osteolysis [8•] , telangiectasias [9] , anti-centromere antibody [9, 10] , and anti-PM/Scl antibody [11] . A recent retrospective multi-center international cohort study of 5218 patients with SSc, where 1290 patients (24.7 %) had calcinosis, confirmed a strong association of calcinosis with digital ulcers (odds ratio (OR) 3.7, 95 % confidence interval (CI) 2.6-5.3, p G 0.0001) and found a novel association with osteoporosis (OR 3.9, 95 % CI 2.1-7.4, p G 0.0001) [3] .
Calcium deposits are made of calcium hydroxyapatite crystals and contain calcium, hydroxides, and phosphates. Although the detailed pathophysiology of calcinosis cutis remains poorly understood, [2•] two general mechanisms of calcification in soft tissues-metastatic and dystrophic calcification-have been described [12•] . Metastatic calcification is the deposition of calcium in normal cutaneous or subcutaneous tissue in the presence of elevated levels of serum calcium and/or phosphate [13, 14] . Dystrophic calcification-the most common presentation of calcinosis cutis occurring in association with SSc [14] -is the deposition of calcified material in diseased tissues as a result of an insult associated with normal serum calcium and phosphate levels [13] . Chronic inflammation and vascular hypoxia are thought to play a role in the tissue damage that serves as a nidus for dystrophic calcification [1•, 15 •]. The role of activated macrophages and inflammation is supported by elevated levels of interleukin (IL)-1 in the serum, and the presence of IL-6, IL-1β, and tumor necrosis factor (TNF)-α in the Bmilk of calcium^(calcium-laden fluid collections) found in patients with juvenile DM [16] . Regarding vascular hypoxia, Davies et al. demonstrated increased expression of the hypoxia-associated glucose transporter molecule (GLUT-1) by immunohistochemistry in skin biopsies of patients with SSc-associated calcinosis. [17] Similarly, the same group evaluated the expression of recognized markers of oxidative stress, the advanced glycation/lipoperoxidation end products (AGEs) and their receptor (RAGE) and concluded that it was greater in the dermis of patients with SSc, especially in those with calcinosis, when compared to healthy controls [18] .
Calcinosis is often clearly palpable or visible on physical examination; however if not, imaging studies may be helpful to confirm the diagnosis. Plain radiography is very sensitive in detecting calcinosis and is recommended as the initial imaging evaluation in patients with ACTD, showing multiple non-specific morphological patterns of calcification (nodular, sheet-like, reticular, amorphous, linear) [5•]. The recent development of a novel radiographic scoring system that evaluates the area coverage, density, and anatomic location of calcinosis affecting the hands in patients with SSc, with excellent reliability (inter-rater reliability intraclass correlation (ICC) = 0.89, 95 % CI 0.86-0.92, and intra-rater reliability ICC = 0.89, 95 % CI 0.8-0.97) should increase the use of plain radiography in routine patient care and clinical trials [19•] . Other imaging techniques such as conventional computed tomography (CT) scans and magnetic resonance imaging (MRI) may be particularly useful in the assessment of lesions involving the trunk, or plaque-like lesions [20•] . Small studies have evaluated the efficacy of ultrasonography (US), multidetector computed tomography (MDCT), and dual-energy computed tomography (DECT) in detecting calcinosis with adequate sensitivity [20•, 21, 22, 23•] . Further studies are necessary to determine whether US, MDCT, and/or DECT might be more useful in the assessment and measurement of calcinosis burden than plain radiography.
Common complications of calcinosis are ulceration at the site of lesions, infection, pain, impaired function, and compression of nerves. In one retrospective study of 78 patients from the Mayo Clinic, the largest cohort of patients with calcinosis in ACTD studied so far, 43 patients (55 %) had ulcer formation in the context of calcinosis cutis, and 54 patients (69 %) had pain associated with calcinosis cutis [4••]. Infection of calcinosis in SSc is underreported, but may also cause pain, and potentially, septicemia [24] .
Treatment of calcinosis General measures
The scarcity of effective options described in the literature makes the treatment of calcinosis a major clinical challenge (Table 1) . Given its relation to hypoxia, general measures to improve blood flow to the extremities, such as avoiding trauma, smoking, stress, and cold exposure, are of crucial importance. Likewise, the medical treatment of Raynaud phenomenon and digital ulcers may play a role in prevention and treatment of calcinosis. Supportive therapies such as pain and anti-inflammatory medications, treatment of infection, and wound care are also a key. If pain is present, acetaminophen and non-steroidal antiinflammatory agents can help; however, narcotics may be necessary for adequate pain control. Corticosteroid injections are well tolerated and palliative and may be effective in reducing secondary inflammation from calcinosis. In one published case of a patient with SSc and calcinosis, injection of the margins of the lesion with 20 mg/mL of triamcinolone acetonide suspension at 4-to 8-week intervals resulted in healing at 12 months [25] . An antibiotic should be prescribed if there is suspicion of superinfection of a calcinotic lesion with clinical features as spreading redness or thick green/yellow discharge. The most frequent organism identified in cultures has been Staphylococcus aureus [24, 26, 27] ; therefore, appropriate empirical treatment with oral antibiotics with good coverage for streptococci and staphylococci, such as cephalexin, dicloxacillin, or clindamycin, are recommended. If calcinosis becomes ulcerated, hydrocolloid membranes such as Duoderm may be useful. Duoderm is a polyurethane film coated with a strong adhesive that protects skin from bacteria and serves as a barrier against further injury. We recommend cleaning the area over the ulcer with hydrogen peroxide 3 % or an antibacterial soap, drying, and covering with antibacterial ointment. Duoderm should be cut approximately 1/2 to 1 in. beyond the wound's margin and applied to the wound after peeling off the adhesive. A tape may be used around the edges of the dressing to aid in keeping it in place. The Duoderm dressing should be changed and cleaned every third day, or sooner if the dressing is oozing a lot of fluid.
Pharmacological treatment
Several pharmacologic therapies aimed at reducing calcinosis, as monotherapy or in combination, have been successful in isolated cases, but none seems to be consistently effective, and the majority of evidence comes from case reports, small case series, and small open-label studies. Furthermore, these agents have not received regulatory approval, since until recently, there have not been any validated outcome measures to study them in randomized clinical trials, and their clinical impact requires a prolonged observation period.
Calcium channel blockers
Calcium channel blockers (CCB) alter the formation and crystallization of the calcium nidus by reducing the intracellular calcium influx in the affected tissues and local macrophages. Diltiazem is the CCB most frequently used for the medical treatment of calcinosis [28••] . Several case reports have shown positive results with diltiazem from 240 to 480 mg/day for 1 to 12 years for calcinosis in SSc patients. [29] [30] [31] In the Mayo Clinic study, diltiazem was effective in 9 out of 17 patients as a first-line therapy for calcinosis [4••]. However, one larger retrospective study of 23 patients with SSc and calcinosis on hand radiographs, where 12 were treated with 180 mg/day of diltiazem, reported a clinically insignificant regression of lesions in three patients [9] . The use of other CCB has been less frequently reported [28••] . In the study by Palmieri et al., one patient who did not tolerate diltiazem received verapamil without effective response [29] . In the Mayo Clinic study, one patient who was treated with amlodipine improved 
Bisphosphonates
Bisphosphonates may be useful in reversing the calcification process by inhibiting macrophage proinflammatory cytokine production and reducing calcium turnover. The association between calcinosis and osteoporosis also suggests that these agents may have a role in the treatment of calcinosis. Conflicting reports regarding the effect of bisphosphonates on calcinosis have been published. A report of six patients with dystrophic calcinosis associated with DM or SSc treated with etidronate for a mean of 10 months demonstrated little success, and moreover showed that all three patients with SSc had clinical and radiologic progression of calcinosis lesions. [32] . However, another SSc patient with extensive calcinosis seen on clinical and radiological examination was treated with etidronate for 1 year and had functional improvement and partial regression of lesions [33] . A more recent case report described clinical and radiological resolution of calcinosis in one limited cutaneous SSc (lcSSc) patient after 6 months of treatment with risedronate for glucocorticoid-induced osteoporosis [34] . Intravenous infusion of pamidronate has been reported to be effective for calcinosis in several case reports/series mostly in DM patients [28••] . Gastrointestinal (GI) side effects such as acid reflux, esophagitis, and esophageal ulceration are the primary concern for patients and may be prevented by taking the medication on an empty stomach first thing in the morning with at least 8 oz of water and avoiding food for half an hour. Given the paucity of evidence, the efficacy of bisphosphonates in calcinosis treatment remains unclear.
Warfarin
By antagonizing vitamin K, warfarin inhibits the production of gammacarboxyglutamic acid, which has calcium and phospholipid-binding properties, and has been found to be increased in patients with calcinosis [15•] . Although several studies suggest that warfarin may be effective for small calcified deposits [35] ,evidence supporting the use of warfarin in calcinosis is conflicting, and its use is not widely accepted. In a double-blind placebo-controlled study of 7 patients with SSc or DM and evidence of substantial and multiple subcutaneous calcifications, three patients received warfarin 1 mg/day for 18 months and four patients received placebo. Two patients in the treatment arm showed decreased extra-skeletal uptake on whole-body bone scintigraphy with injection of technetium 99m-diphosphonate compared with none in the placebo arm. [36] . A case series of three patients with SSc found that two patients had complete resolution of their disseminated calcinosis evaluated at physical examination after 1 year of treatment with low-dose warfarin. The non-responding patient had larger and longer-standing calcinosis [37] . However, in another study of six patients with extensive and long-standing calcinosis (one with SSc) treated with low-dose warfarin for a mean of 14.6 months, five had clinical and radiological worsening of calcinosis [38] . In the Mayo Clinic study, of 19 patients with calcinosis and ACTD, four received warfarin for conditions other than calcinosis, without differences in response compared with the group that did not receive warfarin [4••]. There is a low risk for hemorrhages with warfarin, and rarely, it can cause skin necrosis.
Minocycline
This tetracycline antibiotic has anti-inflammatory and calcium-binding properties. Robertson et al. published a study of nine patients with lcSSc and calcinosis treated with 50 or 100 mg/day of minocycline for a mean of 3.5 years. Eight patients who were able to tolerate the therapy experienced reduction in ulceration and inflammation associated with calcinosis, with a modest decrease in the size of deposits assessed clinically and radiographically. An unexpected effect was the darkening of the calcinosis from white/yellow to blue/black color. Two patients who discontinued the treatment temporarily had recurrence of calcinosis, so the authors recommended cyclic long-term use of minocycline (treatment for 4-8 weeks followed by discontinuation for 3-4 months).
[39] Potential side effects of minocycline are skin pigmentation, dizziness, and rash.
Colchicine
As with minocycline, colchicine seems to be more effective in reducing the inflammation associated with calcinosis than the size of calcium deposits [28••] . Colchicine has anti-inflammatory effects by disrupting leukocyte chemotaxis and phagocytosis through inhibiting microtubule polymerization. Only a few reports of the use of colchicine in patients with SSc have been published [2•]. One patient with SSc and prepatellar calcinosis received 1 mg/ day of oral colchicine and had regression of the associated local inflammation and healing of associated skin ulcers after 2 months of follow-up [40] . Another patient with linear scleroderma and ulcerated cutaneous calcinosis was treated with colchicine 1 mg/day, with healing of the ulcerations after 4 months [41] . In the Mayo Clinic study, three out of eight patients had positive response with colchicine, from which one reported complete resolution of calcium deposits. The authors proposed colchicine as a second choice for calcinosis treatment after CCB [4••]. Colchicine may cause diarrhea, abdominal pain, and more rarely, nerve or muscle damage.
Ceftriaxone
This third-generation cephalosporin is able to bind calcium ions and form insoluble calcium complexes [35] . There is one report of a patient with morphea and multiple calcinosis deposits who experienced significant regression of calcinosis lesions and no new lesions with ceftriaxone (2 g/day) intravenously for 20 days [42] .
Probenecid
Probenecid is an uricosuric drug approved for treatment to prevent gout attacks. It increases renal phosphate clearance and therefore decreases the serum phosphate level, reducing the calcification process. Although not studied in SSc, one patient with juvenile DM and extensive calcinosis who was treated with probenecid up to 500 mg three times daily showed clinical and radiographic improvement after 7 months [43] . It potentially may cause rash, diarrhea, and nephrolithiasis.
Aluminum hydroxide
Aluminum hydroxide also decreases serum phosphate levels by decreasing intestinal absorption. Aluminum hydroxide has been used successfully as a treatment for calcinosis in SLE and several DM patients, with softening and size reduction of calcinosis deposits [44, 45] . One case report of treatment with aluminum hydroxide 30 mL four times daily for calcinosis has been published in a SSc patient, showing good response [46] . The most common side effects of aluminum hydroxide are GI symptoms such as nausea, constipation, discoloration of feces, and abdominal pain. It should be used with caution in patients with renal failure because aluminum may accumulate causing severe phosphate depletion and secondary osteomalacia or osteoporosis.
Intravenous immunoglobulins
The use of intravenous immunoglobulins (IVIG) in the treatment of calcinosis is limited and has shown mixed results. Only one case report in SSc-associated calcinosis treated with IVIG has been published by Schanz et al. They reported that a patient with lcSSc and disabling calcinosis of the left index finger was free of symptoms after 5 months of IVIG [47] . The authors hypothesize that this effect was based on its anti-inflammatory properties, possibly related to suppression of activated macrophages. There is conflicting data on DM-associated calcinosis with positive [48, 49] and negative [50] results. Potential side effects are allergic and infusion reactions, headache, aseptic meningitis, and thrombosis.
Biologic agents
Given the potential role of inflammation and TNF-α in calcinosis, anti-TNF agents may be useful in the treatment of calcinotic lesions. One case report of a patient with SSc-myositis overlap and refractory calcinosis treated with infliximab 3 mg/kg infused at 0, 2, and 6 weeks, and every 8 weeks thereafter, showed reduction in size of calcifications and no new deposits at 41 months in serial pelvic CT imaging [51•] . Rituximab, a chimeric anti-CD20 antibody, may be another promising therapy to treat calcinosis in patients with SSc. One lcSSc patient with extensive calcinotic lesions experienced reduction in size of these on physical examination, and her pain improved substantially after 1 year of treatment with two courses of rituximab (four weekly infusions of 375 mg/m 2 each) 18 months apart [15•] . Another recent case report of a female with lcSSc using the same regimen of rituximab to treat interstitial lung disease and arthritis showed complete resolution of calcinosis in her hands after 7 months of the first infusion [52•] . A case series of 10 SSc patients treated with one or more cycles of rituximab (four weekly infusions of 375 mg/m 2 ) for lung, cutaneous, or articular disease reported that three out of six patients who had calcinosis at baseline had clinical improvement as early as 6 months after the first cycle, which continued to improve through the end of the follow-up period (37 ± 21 months, range 18-72 months) [53] . In contrast, Hurabielle et al. reported the case of a female SSc patient with X-ray evidence of calcinosis on her right wrist, who received two infusions of rituximab (1 g each) at a 2-week interval, and then every 6 months, for interstitial lung disease and arthritis. She subsequently developed extensive calcinosis on her wrist and left elbow [54] .
Emerging therapies
Potential future medical therapies for calcinosis in SSc and other ACTD include more powerful vasodilatory therapies such as phosphodiesterase 5-inhibitors and prostacyclins. Preliminary observations in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry have found that two patients with SScpulmonary arterial hypertension (PAH) and calcinosis treated with subcutaneous treprostinil for PAH simultaneously experienced approximately 50 % radiographic improvement in their calcinosis lesions after 6 months of therapy (Shapiro et al., unpublished data). Other antiinflammatory and immunomodulatory agents such as calcineurin inhibitors, other anti-TNF agents, anakinra (IL-1 receptor inhibitor), or tocilizumab (monoclonal antibody to IL-6) may potentially have an effect on calcinosis. These treatments will need evaluation in prospective studies and randomized controlled trials.
Interventional procedures Carbon dioxide laser vaporization
The carbon dioxide (CO) laser-tissue vaporization procedure is a bloodless technique that allows excellent visualization and vaporization of calcium deposits. Bottomley et al. treated six SSc patients with a total of 21 areas of symptomatic digital calcification of the fingers and found complete resolution of pain and function in 12, partial improvement in 5, little improvement in 2, and recurrence of calcinosis in 2 after a median follow-up of 20 months [55] . In a more recent case report, six affected digits in a lcSSc patient received a single treatment with CO laser vaporization over 5 years, with complete healing and resolution of symptoms after 6 weeks [56] .
Extracorporeal shock wave lithotripsy
Extracorporeal shock wave lithotripsy (ESWL) is a minimally invasive, safe, and well-tolerated technique that may offer effective remission of symptoms and healing of ulcerations related to calcinosis. Sparsa et al. described the case of a lcSSc patient with calcinosis and extensive secondary ulcerations that was successfully treated by ESWL [57] . One prospective study of nine patients (three with SSc) with progressive calcinosis found that after three ESWL sessions at 3-week intervals, there was a reduction in the median area of calcinosis from 3.1 to 1.9 cm 2 . In addition, visual analog scale pain scores (range 0-10) decreased from 7 to 2 after 6 months [58] .
Surgical excision
Surgical excision is treatment of choice for larger and deeper calcium deposits, especially when they are located over tendons, blood vessels, and nerves, whose integrity and function need to be preserved. [59] In the Mayo Clinic experience, all 11 patients who underwent surgical excision alone responded (eight with complete response), as well as 16 out of 17 patients who received medical and surgical therapy (14 with complete response). In contrast, only 7 of 19 patients treated with medical therapy alone had any response (one with complete response) [4••]. Potential risks of surgical excision are slow wound healing, which may lead to skin necrosis, infection, and decreased range of motion [60, 61] . Skin incision with drainage is the simplest procedure, but if this is not sufficient, partial removal can be obtained by curettage as proposed by Saddic et al. They reported excellent clinical outcomes, including decreased pain and short healing times, in one patient with lcSSc who underwent curettage of calcinosis on the tip of his left third finger [62] . An additional approach is a debulking procedure using a high-speed micro-burr to soften calcinosis. A retrospective study of nine SSc patients with calcinosis affecting the digits showed a high degree of patient satisfaction and lower disability scores (measured by Disabilities of the Arm, Shoulder, and Hand questionnaire and the Michigan Hand Questionnaire) with this method. However, no patients reported complete resolution of calcinosis, and seven patients had recurrence [63•] . Referral to a surgeon experienced in treating patients with SSc should be placed in cases of large, localized, and symptomatic calcinosis.
Conclusions
Calcinosis is a common problem affecting one quarter of patients with SSc. It most commonly affects the hands, particularly the fingers, and is related to inflammation and hypoxia. Common and potentially debilitating complications are local inflammation, ulceration, and infection. Although there is no universally effective treatment for calcinosis in patients with SSc, several pharmacological therapies has been proposed as effective, as monotherapy or in combination, including CCB, colchicine, bisphosphonates, warfarin, ceftriaxone, minocycline, probenecid, aluminum hydroxide, IVIG, anti-TNF, and rituximab. Surgical removal of calcinosis remains the mainstay for treatment. Clinical trials using novel outcome measures are necessary to determine the efficacy of current and emerging treatments.
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